Natpar
parathyroid hormone
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Natpar. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Natpar.
For practical information about using Natpar, patients should read the package leaflet or contact their doctor or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Natpar
|
Agency product number |
EMEA/H/C/003861
|
Active substance |
parathyroid hormone
|
International non-proprietary name (INN) or common name |
parathyroid hormone
|
Therapeutic area (MeSH) |
Hypoparathyroidism
|
Anatomical therapeutic chemical (ATC) code |
H05AA03
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Conditional approval |
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Takeda Pharmaceuticals International AG Ireland Branch
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
24/04/2017
|
Contact address |
Block 2 Miesian Plaza |
Product information
01/06/2023 Natpar - EMEA/H/C/003861 - IAIN/0052/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Calcium homeostasis
Therapeutic indication
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.